Amended Statement of Changes in Beneficial Ownership (4/a)
25 Septembre 2020 - 1:29AM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Brown Dennis M |
2. Issuer Name and Ticker or Trading Symbol
Kintara Therapeutics, Inc.
[
KTRA
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Chief Scientific Officer |
(Last)
(First)
(Middle)
12707 HIGH BLUFF DR., SUITE 200 |
3. Date of Earliest Transaction
(MM/DD/YYYY)
11/12/2019 |
(Street)
SAN DIEGO, CA 92130
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
11/14/2019 |
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Options (Right to Buy) | $0.735 | 11/12/2019 | | A | | 250000 | | (1) | 11/12/2029 | Common Stock | 250000 | $0 | 250000 | D | |
Explanation of Responses: |
(1) | This amendment is being filed to update the vesting schedule of the option award made to the reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued employment, 1/6th of the options vested on March 22, 2021, with the remaining shares vesting in equal monthly installments over a period of 30 months commencing on April 22, 2021. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Brown Dennis M 12707 HIGH BLUFF DR., SUITE 200 SAN DIEGO, CA 92130 |
|
| Chief Scientific Officer |
|
Signatures
|
/s/ Anthony Scott Praill, attorney-in-fact for Dennis M. Brown | | 9/24/2020 |
**Signature of Reporting Person | Date |
DelMar Pharmaceuticals (NASDAQ:DMPI)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
DelMar Pharmaceuticals (NASDAQ:DMPI)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about DelMar Pharmaceuticals Inc (NASDAQ): 0 recent articles
Plus d'articles sur Kintara Therapeutics, Inc.